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AbstrAct
Background The complexity of delivering precision 
medicine to oncology patients has led to the creation of 
molecular tumourboards (MTBs) for patient selection and 
assessment of treatment options. New technologies like 
the liquid biopsy are augmenting available therapeutic 
opportunities. This report aims to analyse the experience of 
our MTB in the implementation of personalised medicine in 
a cancer network.
Materials and methods Patients diagnosed with solid 
tumours progressing to standard treatments were referred 
to our Phase I unit. They underwent comprehensive next 
generation sequencing (NGS) of either tumour tissue or 
cell-free circulating tumour DNA (ctDNA) or both. The 
MTB expressed either a positive or negative opinion for 
the treatment of the patients with discovered druggable 
alterations inside a clinical trial, in an expanded access 
programme, with a compassionate use. Afterwards, 
discovered alterations were matched with OncoKB levels 
of evidence for the choice of alteration-specific treatments 
in order to compare MTB outcomes with a standardised 
set of recommendations.
Results NGS was performed either on ctDNA or tumour 
tissue or in both of them in 204 patients. The MTB 
evaluated 173 of these cases. Overall, the MTB proposed 
alteration-specific targeted therapy to 72 patients (41.6%). 
49 patients (28.3% of the total evaluated) were indicated 
to enter a clinical trial. In 29 patients with matched liquid 
biopsy NGS (lbNGS), tumour tissue NGS (ttNGS) and MTB 
evaluation, the MTB changed the treatment strategy 
coming from standardised recommendations based on 
lbNGS and ttNGS alone in 10 patients (34.5%), thanks to 
the evaluation of other clinical parameters. In our cohort, 
lbNGS was more likely, compared with ttNGS, to detect 
point mutations (OR 11, 95% CI 2.9 to 24.1, p<0.001) and 
all-type alterations (OR 13.6, 95% CI 5.5 to 43.2, p<0.001) 
from the same genes of matched patients.
Conclusions Our MTB allows patients with refractory 
cancer to be included in clinical trials and improves 
the precision of clinical decisions compared with a 
standardised set of mutation-driven recommendations.
IntRoduCtIon
With the advent in clinic of next generation 
sequencing (NGS) panels, an increasing 
amount of therapeutic choices have become 
available, particularly for patients with 
limited standard of care options.1 NGS 
panels can provide the treating physician 
Key questions
What is already known about this subject?
 ► The use of both molecular tumour board and liquid 
biopsy has already been described in the clinical 
practice. It is acknowledged that molecular tumour 
boards can be used for the selection of treatment 
following the use of NGS panels from solid tumour 
tissue DNA. Also, it has already been shown that the 
next generation sequencing (NGS) performed in the 
circulating DNA can reach the same level of sensitiv-
ity for the detection of genetic alterations compared 
with the NGS performed on DNA coming from solid 
tumour biopsies or gross masses.
What does this study add?
 ► We were the first to compare the impact of the 
molecular tumour board decision to a set of stan-
dardised list of evidence level for the choice of al-
teration-driven recommendations. Also, we were the 
first to describe the activity of a molecular tumour 
board which used the results of NGS performed on 
circulating DNA. Finally, this study shows a real-life 
comparison between NGS panels performed on cir-
culating DNA and DNA from solid tumour biopsies or 
gross tumour masses.
How might this impact on clinical practice?
 ► Physicians might want to implement molecular tu-
mour boards in their clinical practice.
 ► Physicians might choose to prefer the use of liquid 
biopsy DNA over the use of DNA from old forma-
lin-fixed paraffin-embedded samples.
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with a variably extensive list of druggable alterations that 
can subsequently lead to the enrolment of that patient 
in a trial, treatment of that patient in an expanded 
access programme or, also, with an off-label indication. 
Treating physicians, however, are not always trained to 
interpret the reports of these analyses. Also, treatment 
options associated with newly discovered druggable 
alterations have often limited evidence of efficacy in the 
daily practice.2 As a result, the treating physician has 
to carefully evaluate the potential benefits of a clinical 
trial or of an off-label therapy taking into consideration 
other therapeutic choices, particularly best supportive 
care.
Targeted therapy in non-small cell lung cancer 
(NSCLC) based on identification of seven genomic 
targets has been shown to double overall survival in 
academic and community settings.3 4 However, the use of 
NGS panels in a broader array of cancer types has proven 
to improve the patients’ outcomes in some studies but 
not in others.5 The Molecular Screening for Cancer 
Treatment and Optimisation trial showed that patients 
treated with off-label alteration-driven treatments had 
improved progression free survival compared with their 
previous treatments.6 However, in the SHIVA trial, no 
difference were observed in overall survival for patients 
randomised to receive either alteration-driven targeted 
therapy or physician-choice chemotherapy.7 Taking into 
consideration, these contradictory clues we believe that, 
in order to fully exploit the potentials of NGS driven 
therapy, a formal entity bringing interdisciplinary exper-
tise into evaluation of patients with advanced cancer 
should exist to indicate when alteration-driven treat-
ment is advisable.
The complexity of delivering precision medicine to 
oncology patients in the context of a public healthcare 
system further suggested the need to create molecular 
tumour boards (MTBs) to assess when extensive molec-
ular testing for tumour profiling was appropriate and, 
also, to discuss therapeutic chances of patients with newly 
discovered druggable alterations.8 It has already been 
shown in a diverse set of clinical scenarios that interdis-
ciplinary tumour boards can result in significant changes 
in treatment decisions.9–11 However, aside from changes 
in treatment plans and increased enrolment of patients in 
clinical trials, the impact of MTBs on treatment outcomes 
has not yet been studied.12–14
We expected that the MTB could improve the preci-
sion of a single physician choice based on outcomes of 
high throughput molecular testing. The aim of this study 
was to retrospectively measure the impact of MTB discus-
sion on physician decision-making regarding treatment 
in patients with NGS panels data available. To test it, we 
compared how evidence-based recommendations for 
druggable alterations match with the indications of our 
MTB. Further, we compared lbNGS and ttNGS ability 
to provide the physician with valid treatment options in 
patients with no further therapeutic options available.
MetHods
Patient recruitment
All the patients referred to our Phase I unit of the 
oncology department of the Antwerp University Hospital 
from May 2013 to September 2017 were eligible for 
the participation in the study. During the visit, NGS 
sequencing was proposed to patients who could poten-
tially benefit from finding of druggable alterations. 
The criterion for preferring lbNGS over ttNGS was the 
absence of sufficient tumour tissue and the clinical unfea-
sibility of a re-biopsy. In patients with both lbNGS and 
ttNGS, the former was proposed to the patient in case the 
latter did not provide convincing results. Patients with a 
life expectancy of less than 3 months or with other very 
valid therapeutic chances were excluded. No restrictions 
were applied related to age or tumour type. Notably, for 
some patients for which chemotherapeutic agents with 
an expected low clinical benefit were available, molecular 
analysis were considered anyway, and, eventually, these 
patients started a new alteration-driven treatment either 
immediately—thus stopping chemotherapy—or as soon 
as they progressed from chemotherapy; this decision was 
taken, of course, according to the opinion of the MTB. 
These molecular gene panels were not reimbursed by 
insurance companies in Belgium. On their first visit to 
our unit, patients were informed about the potentials and 
the limitations that these techniques could offer for the 
treatment selection. After ensuring that the patients had 
understood the information received, they signed the 
corresponding informed consent and then the tumour 
sample was sent for processing.
Circulating free tumour dnA sequencing
The commercial platform Guardant360 was used to 
detect alterations of 73 related cancer genes15 in cell-free 
circulating tumour DNA (ctDNA) in a Clinical Labora-
tory Improvements Act-licensed, College of American 
Pathologists-accredited, New York State Department of 
Health-approved laboratory (Guardant Health, Redwood 
City, California, USA). The methods for ctDNA isolation 
and sequencing are extensively described elsewhere.16 
Briefly, two blood samples were collected for each patient 
in 10 mL Streck Cell-Free DNA Blood Collection (Streck) 
tubes; these tubes, kept in room temperature, ensure 
high-quality preservation of cell-free (cfDNA) longer (up 
to 7 days at room temperature) than EDTA tubes17 and 
they proved to maintain cfDNA quality in 3 days long ship-
ping-like experimental conditions (an important consid-
eration as our cancer centre is a continent away).18 CfDNA 
was isolated from plasma, concentrated with Agencourt 
Ampure XP beads and finally prepared for sequencing. 
The minimal amount required for library preparation was 
5 ng.16 After molecular barcoding, massively parallel NGS 
was conducted on an Illumina HiSeq, followed by bioinfor-
matic error suppression of false positives. After complete 
sequencing of critical exons in target genes, all four major 
types of genomic alterations were reported, single nucle-
otide variants (SNVs) in all genes, and insertions and 
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deletions (indels), fusions and copy number amplifica-
tions in selected genes. Variant allele fraction was reported 
as the percentage of mutated DNA molecules divided by 
the total cfDNA molecules at a given genomic position.
tumour tissue dnA sequencing
Tumorous DNA was extracted from patient resection 
specimens or biopsies by the following procedure. Based 
on H&E slides, the pathologist selected the paraffin 
block with the most dense tumour, designated a region 
of interest (ROI) and estimated the tumorous cell frac-
tion from this ROI. Only samples with a tumorous cell 
fraction of >10% were included. Macrodissection of the 
designated area was performed from 10 unstained slides, 
and DNA was extracted by means of the QIAamp DNA 
Mini QIAcube Kit making use of the QIAcube device 
according to the manufacturer’s instructions (Qiagen). 
Subsequently, sample preparation and target capture were 
performed by means of the ClearSeq HS Target Enrich-
ment System (Agilent Technologies), enabling detection 
of relevant regions from the following 47 genes: ABL1, 
AKT1, ALK, AR, ATM, BRAF, CDKN2A, CSF1R, CTNNB1, 
EGFR, ERBB2, ERBB4, FANCA, FANCC, FANCF, FANCG, 
FGFR1, FGFR2, FGFR3, FLT3, HRAS, IDH1, IDH2, JAK2, 
JAK3, KIT, KRAS, MAP2K1, MAP2K2, MAP2K4, MET, 
NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, 
PTEN, RET, RUNX1, SMAD4, SMD, SRC, STK11, TP53, 
VHL and WT1. Pooled samples were sequenced on a 
MiSeq Personal Sequencer (Illumina) with a maximum 
of 24 samples (+external control) per run. Data analysis 
was performed with BaseSpace and SeqNext for calling 
and annotation of variants.
MtB meetings
The molecular tumour board (MTB) met every 2 weeks. 
Regular attendees consisted of medical oncologists, 
general and molecular pathologists, a bioinformatics 
expert, a molecular biologist, a geneticist and a nurse 
navigator. If needed, specialists in specific areas, such as 
gynaecologists, thoracic surgeons or similar were invited 
for further expertise in specific cases. Each case was 
discussed in multidisciplinary group sessions. Apart from 
clinical data, the MTB took into consideration the results 
from NGS panels and, when available, also data coming 
from other molecular analysis such as fluorescent in situ 
hybridisation, immunohistochemistry and PCR. For each 
case, the MTB discussed which was the best treatment and 
expressed a recommendation accordingly. For patients 
discovered with druggable alterations, the different indi-
cations comprised standard of care treatments, enrol-
ment in a clinical trial, expanded access programmes 
or compassionate use. Patients without any evidence of 
druggable alterations were evaluated for alternative ther-
apeutic chances and, eventually, referred to their refer-
ence centre for best supportive care.
Comparison of MtB and nGs outcomes
In order to evaluate the impact of MTB decisions, we 
decided to compare its outcomes with a set of standardised 
evidence levels for the treatment of patients with specific 
alterations. To this point, we downloaded the OncoKB19 
actionable variants list that comprises (October 2017) a 
list of 390 recommendations for 77 actionable genes and 
six recommendations for resistance to therapy. Recom-
mendations level goes from 1 to 4 and are reported in 
online supplementary table 1. We matched each alter-
ation with its corresponding level of evidence for that 
particular cancer type. Afterwards, we determined which 
was the treatment with highest level evidence provided 
to each patient based on his/her actual alterations. In 
our work, this value represented a standardised score to 
assess the likelihood of the patient to undergo an altera-
tion-driven treatment—logically, the higher is the level of 
evidence for an alteration-driven treatment associated to 
a patient’s mutation, the more appropriate would be for 
that patient to undergo that specific treatment. Neverthe-
less, this score was ‘blind’ far what concerns the evaluation 
of every single clinical scenario details: such an evaluation 
is supposed to be the adjunct contribution of our MTB.
statistical analysis and data handling
Mean, median and/or 95% CI were reported whenever 
deemed appropriate. Absolute value and frequency were 
reported in descriptive tables. Mann-Whitney test was 
used to compare differences of distributions for inde-
pendent non-parametric sets of data. Pearson χ2 was used 
to compare difference in proportions for independent 
cohorts; Fisher’s exact test was used in place of Pearson χ2 
when dealing with small and/or very asymmetric subsam-
ples. McNemar χ2 was used to compare difference in 
proportions for paired sample. Univariate linear regres-
sion was used to assess dependency of independent, 
continuous, normally distributed variables; log transfor-
mation was applied when deemed appropriate to better 
fit the linear model. All recorded data were imported and 
analysed in R V.3.4.1.20 Most of the graphics were elabo-
rated with R package ggplot2.21
Results
Patients characteristics
We performed the liquid biopsy NGS (lbNGS) on 
53 samples from 46 patients from November 2016 to 
September 2017 with Guardant 360 platform. lbNGS 
population was particularly enriched for NSCLC (n=15, 
30.4%). Tumour tissue NGS (ttNGS) was performed on 
195 samples from 186 patients. The median number of 
genes sequenced for each ttNGS sample was 47 (range: 
1–96; in 75% of the patients the number of sequenced 
gene was between 44 and 49) (online supplementary 
figure 1). Most common cancer types in the ttNGS cohort 
were lung cancer (n=37, 19.9%), colorectal cancer (n=26, 
14.0%) and pancreatic cancer (n=22, 11.9%). Compre-
hensive patients characteristics are listed in online supple-
mentary table 2. Twenty-nine patients received both at 
least one ttNGS and one lbNGS determination.
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lbnGs outcomes
We detected 321 different alterations from lbNGS 
samples. There were no lbNGS sequencing failures; 
however, in six samples (11.3%) no alterations could be 
detected (online supplementary figure 2). The median 
number of alterations observed in each sample was 3 
(range: 0–41). The vast majority were point mutations 
(n=199, 62.0%) and amplifications (n=94, 29.3%) (online 
supplementary figure 3). Alterations of TP53 gene were 
the most frequent (n=39) followed by EGFR (n=25), APC 
(n=21), PIK3CA (n=20), KRAS (n=18) and MET (n=18) 
(online supplementary figure 4). The median amount of 
ctDNA (representing the variant allele fraction) detected 
in each sample was 0.054% of the total cfDNA (range: 
0%–27.6%) (figure 1). Intriguingly, univariate analysis 
showed a significant positive correlation between the 
level of ctDNA and the number of alterations detected 
(1.97 increase in log of total alteration discovered for 
every unitary increase of log of % of ctDNA; adjusted 
R2=0.66; p=3.4e−12) (figure 1). Five patients with lung 
adenocarcinoma (LUAD) underwent two liquid biopsy 
and one patient with small cell lung cancer underwent 
three liquid biopsies, each at subsequent lines of progres-
sion. Number of alterations was bigger for lung squa-
mous cancer than for LUAD (median difference of nine 
mutations; Mann-Whitney: p=0.026; two couples of paired 
samples values were each substituted with the respective 
average value of the two in order to obtain independent 
observations). Every alteration was matched with OncoKB 
evidence level for targeted therapy.19 Figure 2 shows the 
highest level recommendation that was found for each 
sample. An R1 alteration (alteration proven to induce 
resistance to an approved treatment and thus warranting 
discontinuation of that treatment) was found in 14 out of 
53 (26.4%) liquid biopsy samples.
ttnGs outcomes
We detected 264 different alterations from ttNGS 
samples. The amount of samples with no alterations 
detected was 61 out of 195 (31.3%); probably, the 
higher frequency of negative results in ttNGS samples 
compared with LB was due the lower average number 
of genes sequenced. The median number of altera-
tions detected with ttNGS was 1 (range: 0–21). TP53, 
KRAS and APC were the most frequently mutated 
genes—respectively, 39.8%, 18.9% and 16.4% of the 
samples in which each gene was sequenced (online 
supplementary figure 5). Figure 2 shows which 
was the highest level recommendation that could 
be given to each sample according to the OncoKB 
scale. Compared with ttNGS, lbNGS could provide 
more level ≥3b recommendations (43.4% vs 13.3%; 
P<0.0001) and level 1 recommendations trended to 
lower a lower value (7.5% vs 3.1%; Fisher’s exact test: 
p=0.22); the fact that less genes were sequenced in 
ttNGS samples compared with lbNGS samples prob-
ably plays a role in this difference.
Comparison of ttnGs and lbnGs in matched patients
In total, 29 patients received at least one LB and one NGS 
sequencing in their primary tumour tissue. In these 29 
samples, the mean and the median of sequenced genes in 
the tumour tissue were, respectively, 34.6 and 47 and only 
four patients had less than 10 genes sequenced in their 
tumour tissue.
First, we measured the positive concordance for the 
detection of alterations in genes sequenced in the same 
patient with both lbNGS and ttNGS; due to the differ-
ences in the panels employed, a direct comparison of 
lbNGS and ttNGS concordance was possible only for a 
small subset of sequenced genes. Among these genes, 
a total of 53 point mutations were detected, respec-
tively, 37 by lbNGS alone, five by ttNGS alone and 11 
by both of them (OR 7.4 favouring the use of lbNGS, 
95% CI 2.9 to 24.1; McNemar’s χ2: p=4.4×10−7). Thus, 
lbNGS and ttNGS could detect, respectively, 90.6% 
and 30.2% of the total point mutations (figure 3). 
This considerable difference was observed also when 
considering all kind of alterations (68, 5 and 18 alter-
ations were detected, respectively, by lbNGS alone, 
ttNGS alone and both lbNGS and ttNGS; OR 13.6, 
95% CI 5.5 to 43.2; McNemar’s χ2: p=3.4×10−15).
Second, we compared the ability of lbNGS and ttNGS of 
providing patients with an alteration-driven OncoKB-an-
notated recommendation. NGS on tumour tissue and 
Figure 1 Distribution of cell free tumour DNA between 
liquid biopsy next generation sequencing samples and 
correlation with alterations burden. In the dot plot (left), 
the blue dot and the blue line represent, respectively, the 
median and the 25th to 75th percentiles range. In the 
scatterplot (right), X axis and Y axis are inverted.
Figure 2 OncoKB evidence levels from liquid biopsy next 
generation sequencing (lbNGS) (n=53) and tumour tissue 
NGS (ttNGS) (n=195) in all available samples.
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LB were perfectly concordant for patients OncoKB level 
one recommendations (n=2); nevertheless, the chance 
of finding a ≥3b level recommendations was signifi-
cantly higher in the lbNGS group (OR 11.0, 95% CI 
1.6 to 473.4; McNemar’s χ2: p=0.006). Out of 29 patients 
with matched lbNGS and ttNGS, for 11 patients (37.9%) 
the LB provided an additional clinical benefit compared 
with tumour tissue NGS alone: these patients had no 
alterations detected, not OncoKB-annotated alterations 
detected or grade 4 alterations detected in the ttNGS but 
the LB could provide the patients with an OncoKB ≥3b 
recommendation for a targeted therapy (figure 4). 
Whereas for these 11 patients LB provided an additional 
clinical benefit compared with tumour tissue NGS alone, 
the opposite is true only for one patient (sample id 
A56133) (figure 4).
Contributions of the molecular tumour board
In total, the MTB expressed an opinion for 173 unique 
patients. All the patients that underwent lbNGS and 150 
out 195 (76.9%) of the ttNGS samples were evaluated by 
the MTB. For 72 (41.6%) of them, the MTB suggested 
initiation of a targeted therapy based on the molecular 
analysis of lbNGS, ttNGS or other available data. Forty-nine 
of these 72 patients (28.3% of the total) were suggested 
to enter a clinical trial; the remaining 23 patients were 
proposed either an expanded access programme or an 
off-label drug.
Of the 53 cases in the lbNGS cohort, the MTB could 
provide the patient with a treatment recommendation 
in 18 cases (34.0%) in which the liquid biopsy did not 
provide any ≥3b level recommendation (figure 5); more-
over, among the 23 cases with a lbNGS ≥3b level recom-
mendation, the MTB proposed an alternative treatment to 
the molecular-driven targeted therapy in almost one third 
of the patients (n=7; 30.4%). In the ttNGS cohort, the 
MTB could provide the patient with a treatment recom-
mendation in 43 cases (28.6%). Even in this cohort, a 
remarkable proportion of patients with druggable molec-
ular alterations were not considered for molecular driven 
target therapy—9 out of 24 (37.5%).
In order to compare MTB, lbNGS and ttNGS recom-
mendations in homogenous cohorts, we analysed the 
outcomes in 29 samples with matched MTB recommen-
dations, lbNGS and ttNGS available (online supplemen-
tary table 3 lists NGS profiles and clinical features of the 
patients). In 17 cases (58.6%), the MTB, based on the 
molecular profile of each sample, expressed a positive 
opinion for the treatment of the patient with a targeted 
therapy—either with a standard of care treatment in 
a clinical trial or in an expanded access programme. 
MTB decisions had a measurable impact on the choice 
of the treatment: for 10 of the 29 patients (34.5%), the 
Figure 3 On the left, Euler-Venn diagram of point 
mutations detected by lbNGS and ttNGS on matched genes 
from the same patients; on the right, the percentage of point 
mutations detected by lbNGS and ttNGS on matched genes 
from the same patients. lbNGS, liquid biopsy NGS; NGS, 
next generation sequencing; ttNGS, tumour tissue NGS. 
Figure 4 Summary of indications of targeted therapy according to the MTB decision (second row), highest level OnoKB 
recommendations for LB-detected alterations (third row) and highest level OncoKB recommendations for tumour tissue-
detected alterations (fourth row). lbNGS, liquid biopsy NGS; MTB, molecular tumour board; NGS, next generation sequencing; 
ttNGS, tumour tissue NGS. 
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MTB expressed an opinion discordant with the result of 
the molecular analysis. In particular, for 4 of 16 patients 
(25.0%) with an OncoKB treatment evidence level ≥3b 
the MTB did not propose any targeted therapy; the 
MTB changed the treatment indications mostly because 
other therapeutic chances were actionable. At the same 
time, the MTB proposed to 6 of the 13 patients (46.2%) 
without any OncoKB treatment evidence level ≥3b to 
enter a clinical trial.
dIsCussIon
In this paper, we report the impact of an interdiscipli-
nary MTB on the treatment decision for patients with 
advanced solid cancers. Previous studies reported only 
MTB assessments without comparison to other standard-
ised measures12 13; other papers compared the benefit of 
gene sequencing and subsequent target therapy.6 22 To 
our knowledge, we were the first to compare MTB deci-
sions with a standardised set of evidence-based levels, thus 
making it possible to measure the impact of MTB deci-
sions as a change of patient treatment.
In our experience, the majority of NGS-detected 
druggable alterations were not Food and Drug Admin-
istration/European Medicines Agency-approved for the 
treatment of the respective cancer type; this is consistent 
with previous reports.23 In this scenario, a balance has to be 
made between the expected benefit of a specific targeted 
therapy and other possible interventions—including 
palliative care. Our MTB could simultaneously evaluate 
all these aspects, melding the best evidence regarding 
each genetic alteration with a patient-specific approach. 
As a result, we could exploit one or more NGS panels to 
assign a remarkable number of patient to a clinical trial 
(28.3%), while, simultaneously, the use of molecular 
alterations for the patients’ clinical evaluation was imple-
mented by the contribution of the MTB. Previous positive 
evidence for the use of NGS panels in improving patients 
outcomes in pan-cancer cohorts5 6 24 are somehow coun-
teracted by negative results of the SHIVA trial.7 Intrigu-
ingly, in this last example, the function of the molecular 
board included only the choice of therapy for cases in 
which there were more than one actionable mutation. 
We believe that the MTB should, like in our case, include 
patients with a single alteration in order to indicate 
whether a druggable alteration is worth being targeted. 
It must be noted that our report represents a real world 
application of different technologies available for the 
discovery of druggable alterations in patients with cancer. 
It differs from previous trials as their aim was to assess 
an eventual superiority of alteration-driven treatment to 
standard of care. As these trials have opened a possibly 
revolutionising way of selecting treatments for patients 
with cancer, our aim was to describe the application of 
these methods in the real world and with the support 
of a multidisciplinary MTB. The relatively high number 
of patients considered for a clinical trial compared with 
previous studies is due to the facts that (1) some of the 
patients received a positive recommendation from the 
MTB but, subsequently, their clinical conditions deteri-
orated rapidly preventing them from participating and 
(2) for different patients a trial with immunotherapeutic 
agents was proposed.
In this heavily pretreated, advanced pan-cancer cohort, 
we found that lbNGS provided an additional clinical 
benefit compared with tumour tissue NGS alone in 37.9% 
of patients—mostly OncoKB ≥3 b. Despite a clear role of 
the differences between the panels used for lbNGS and 
ttNGS, this result was reinforced by the higher number 
of alterations detected by lbNGS in matched genes from 
matched patients. However, the sample size studied here 
was modest. Therefore, we feel that the difference in 
recommendations’ levels provided by the different NGS 
panels alone should not be regarded as a declaration of 
superiority of one of the two; it should, rather, be consid-
ered a further confirmation of feasibility and reliability 
of lbNGS panels in clinical practice. Also, we believe that 
the different timing of lbNGS and ttNGS in matched 
patients—ttNGS might have been performed on years old 
samples—and the selection bias for the use of lbNGS—
patients with an inconclusive ttNGS were more likely to 
be chosen for the lbNGS—might have played a role in the 
sharp difference; nevertheless, we highlight once again 
that the value of this report resides in its adherence to the 
real-world practice, in which it is not important to eval-
uate two different platforms within comparable experi-
mental conditions but rather it is crucial to provide the 
patient with the highest number possible of reliable alter-
ation-driven therapeutic alternatives. Our report, along 
with other previous studies, poses the doubt as to whether 
the ttNGS has to be considered the gold standard and the 
lbNGS only a less sensitive method.
It has been reported that the lack of standard criteria 
to define actionability is a major challenge in the imple-
mentation of MTBs.8 Annotating evidence-based gene 
Figure 5 Euler-Venn diagram showing concordance of 
MTB decision with OncoKB recommendations for molecular 
driven targeted therapy; comparison of (A) MTB and 
ttNGS cohort, (B) MTB and lbNGS cohort and (C) matched 
MTB, lbNGS and ttNGS. lbNGS, liquid biopsy NGS; MTB, 
molecular tumour board; NGS, next generation sequencing; 
ttNGS, tumour tissue NGS.
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alteration panels could allow us to compare different 
NGS techniques outcomes both between them and with 
our MTB decisions. The choice of the OncoKB evidence 
level was made after an internal consultation; we do not 
assess that this list is superior to others that have been 
published.25 We encourage that other groups, in the 
future, rely on this approach to measure the effect of 
MTB implementation.
As an incidental finding, we report a positive and 
statistically significant correlation between the amount 
of ctDNA and the number alterations detected in each 
patient. We do not know whether this could depend on 
a real increase in ctDNA in highly mutated tumour or in 
a lack of sensitivity of the detection method in the pres-
ence of lesser amount of ctDNA. If the latter hypothesis 
was true, this result would suggest that patients with lower 
ctDNA levels would have less chance to have an alteration 
detected and therefore to enter a clinical trial. Neverthe-
less, we believe that this conclusion must be confirmed by 
an ad hoc study.
A major limitation of this study was the difference of 
the lbNGS and ttNGS cohorts; as such, in only 29 patients 
matched NGS panels could be compared. However, we 
focused on impact on treatment decisions and OncoKB 
levels of actionability as a superior standard for compar-
ison between assays than gene-level concordance. More-
over, MTB evaluation for the treatment assessment lacked 
a control representing routine clinical and widespread 
practice for this kind of decisions—such as a blinded 
single clinical oncologist evaluation. The use of different 
commercial panels for ctDNA NGS and tumour tissue 
DNA NGS, while on one side represents a weak point as 
different number and type of genes were analysed for 
each patient, can be considered as a strength as these 
platforms have been extensively validated and it eases 
eventual future comparisons.
ConClusIon
In conclusion, the use of MTB can allow a remarkable 
number of patient to undergo enrolment in a clinical 
trial or treatment with a targeted therapy while, simulta-
neously, delineating precise patient-specific therapeutic 
strategies.
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